
The development of antipsychotic medications has significantly shaped the landscape of psychiatric treatment. Although newer agents display a lower prevalence of movement disorders than their predecessors, the risk remains substantial. The widespread use of antipsychotic medication demands vigilant monitoring, especially considering the potential stigmatization and patient distress associated with these movement disorders. The article emphasizes the importance of recognizing and managing antipsychotic-induced movement disorders, highlighting their potential to affect treatment adherence and clinical assessment.
Like
Save
Share